Catalyst Pharmaceuticals Inc Earnings

Catalyst Pharmaceuticals Inc’s revenue jumped 43.56% since last year same period to $141.42Mn in the Q1 2025. On a quarterly growth basis, Catalyst Pharmaceuticals Inc has generated -0.28% fall in its revenue since last 3-months.

Catalyst Pharmaceuticals Inc’s net profit jumped 143.77% since last year same period to $56.74Mn in the Q1 2025. On a quarterly growth basis, Catalyst Pharmaceuticals Inc has generated 1.43% jump in its net profits since last 3-months.

Catalyst Pharmaceuticals Inc’s net profit margin jumped 69.8% since last year same period to 40.12% in the Q1 2025. On a quarterly growth basis, Catalyst Pharmaceuticals Inc has generated 1.72% jump in its net profit margins since last 3-months.

Catalyst Pharmaceuticals Inc’s price-to-earnings ratio after this Q1 2025 earnings stands at 14.32.

Catalyst Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at 0.53 - a 64.59% jump from last quarter’s estimates.

Catalyst Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at 0.53.

Catalyst Pharmaceuticals Inc’s earning per share (EPS) jumped 257.89% since last year same period to 0.68 in the Q1 2025. This indicates that the Catalyst Pharmaceuticals Inc has generated 257.89% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Catalyst Pharmaceuticals Inc’s return on assets (ROA) stands at 0.19.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Catalyst Pharmaceuticals Inc’s return on equity (ROE) stands at 0.29.